Market Research Logo

EpiCast Report: Attention-Deficit/Hyperactivity Disorder - Epidemiology Forecast to 2024

EpiCast Report: Attention-Deficit/Hyperactivity Disorder - Epidemiology Forecast to 2024

Summary

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common childhood disorder that can continue through adolescence and adulthood. Symptoms include higher than normal levels of impulsivity and inattention that impair an individual’s ability to function properly in various settings like school or work. Studies show a greater number of boys being diagnosed with ADHD compared with girls, with male to female ratios reported to range from 3:1 to 9:1, dependent on the study setting (general population or clinics). There are three distinct subtypes of ADHD: predominantly inattentive type (ADHD-I), predominantly hyperactive-impulsive type (ADHD-H), and combined type (ADHD-C). Common comorbidities include learning disabilities, oppositional defiant disorder, conduct disorder, obsessive compulsive disorder, tic disorders, substance use disorders, anxiety disorders, bipolar disorder, and depression. Genetic studies have conclusively demonstrated that genetic influences play a role in the etiology of ADHD.

GlobalData epidemiologists forecast the diagnosed prevalent cases of ADHD in the 7MM to grow by 2.86% per year over the next 10 years, from 26,540,792 cases in 2014 to 34,129,001 cases in 2024. In the 7MM, the US will have the highest number of diagnosed prevalent cases throughout the forecast period, with 21,217,302 cases in 2014 and 28,833,163 cases in 2024. In the 7MM, the age group 18 years and older had the highest number of diagnosed prevalent cases of ADHD in 2014, contributing 18,870,635 cases, consisting of 71.10% of the total. Across the 7MM, the diagnosed prevalent cases of ADHD are higher in men compared to women, with 17,153,298 (64.63%) cases occurring in men and 9,387,494 (35.37%) cases occurring in women in 2014. The ADHD subtype in children and adolescents with the highest number of diagnosed prevalent cases was ADHD-I, with 3,175,915 cases or 41.43% of the total in the 7MM in 2014, while the ADHD subtype in adults with the highest number of diagnosed prevalent cases was ADHD-C, with 10,770,130 cases or 57.07% of the total.

GlobalData epidemiologists utilized comprehensive, country-specific data from registries and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of ADHD. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for the diagnosed prevalent cases of ADHD. Furthermore, the use of uniform methodology across markets allows for meaningful global comparisons of the diagnosed prevalent cases of ADHD.

Scope

  • The Attention-Deficit/Hyperactivity Disorder (ADHD) EpiCast Report provides an overview of the risk factors and global trends of ADHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of ADHD diagnosed prevalent cases segmented by age group (3-5 years, 6-12 years, 13-17 years, and 18 years and older), sex, disease subtype, and comorbid disorder in these seven markets.
  • The ADHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The ADHD EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global ADHD market.
  • Quantify patient populations in the global ADHD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ADHD therapeutics in each of the markets covered.
  • Identify the percentage of ADHD diagnosed prevalent cases by age, sex, disease subtype, and comorbid disorder.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global Trends
2.3.1 US
2.3.2 5EU
2.3.3 Japan
2.4 Forecast Methodology
2.4.1 Sources Used Tables
2.4.2 Forecast Assumptions and Methods
2.4.3 Sources Not Used
2.5 Epidemiological Forecast for ADHD (2014-2024)
2.5.1 Diagnosed Prevalent Cases of ADHD
2.5.2 Age-Specific Diagnosed Prevalent Cases of ADHD
2.5.3 Sex-Specific Diagnosed Prevalent Cases of ADHD
2.5.4 Age-Standardized Prevalence of ADHD
2.5.5 Diagnosed Prevalent Cases of ADHD by Subtype
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologists
3.2.2 Managing Epidemiologists
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.3 About GlobalData
3.4 About EpiCast
3.5 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for ADHD
Table 2: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD
Table 3: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages 3‒17 Years
Table 4: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages ≥18 Years
Table 5: 7MM, Sources Not Used in Epidemiological Analysis of ADHD
Table 6: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages ≥3 Years, Select Years, 2014-2024
Table 7: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, N (Row%), 2014
Table 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages ≥3 Years, N (Row %), 2014
Table 9: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N (Row %), 2014
Table 10: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages ≥18 Years, Adults, N (Row %), 2014
1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages ≥3 Years, Selected Years, 2014-2024
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, 2014
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages ≥3 Years, 2014
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of ADHD, Ages ≥3 Years , 2014
Figure 5: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N, 2014
Figure 6: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages ≥18 Years, Adults, N, 2014

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report